Aldeyra Therapeutics Inc
Change company Symbol lookup
Select an option...
ALDX Aldeyra Therapeutics Inc
RBLX Roblox Corp
JMIA Jumia Technologies AG
MYDX MyDx Inc
WHF WhiteHorse Finance Inc
INDB Independent Bank Corp (Massachusetts)
SNOW Snowflake Inc.
FAUDX Strategic Advisers® Short Duration Fund
FFBC First Financial Bancorp
SMEBF Sime Darby Bhd
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.

Closing Price
$9.07
Day's Change
-0.11 (-1.20%)
Bid
--
Ask
--
B/A Size
--
Day's High
9.27
Day's Low
8.91
Volume
(Light)
Volume:
435,648

10-day average volume:
746,646
435,648

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.